Hepatic insulin-like growth factor-I (IGF-I) receptor and mRNA expression in experimental hepatocellular carcinoma (HCC)

I. H. Mckillop, T. Johnson, P. Sabharwal, C. Schmidt, P. A. Cahill, J. V. Sitzmann

Research output: Contribution to journalArticle

Abstract

Insulin-like growth factor-I (IGF-I) is a single-polypeptide chain cytokine involved in tissue growth and differentiation. We hypothesized that altered IGF-I receptor expression in conjunction with changes in IGF-I production may be a key factor in the development and/or progression of experimental HCC. Tumorigenic H4IIE hepatoma cells were inoculated into the right hepatic lobe of ACI rats resulting in reproducible parenchymal tumor growths 14 days post-inoculation. Circulating levels of GH and IGF-I were determined in serum at 2 day intervals post-inoculation (day 2 to day 14) using RIA's. These data demonstrated no significant changes in circulating GH or IGF-I levels throughout the duration of HCC development (n=5). Cell fractions were prepared from right and left hepatic lobes of both tumor bearing and sham operated (saline vehicle only) animals 14 days post-inoculation. Western blot analysis was then performed using a polyclonal antibody raised against the IGF-I receptor that detects both a 130kDa protein (receptor α-subunit), and a second 180kDa protein (receptor pro-α-subunit). Both the α-subunit and the pro-α-subunit protein were significantly elevated in non-tumor bearing lobes (NT) as compared to tumor (T) and sham operated (Sh) membranes (246±24% and 141±14% respectively, n=5, p<0.05). No significant differences were observed between sham operated and tumor tissue. Northern blot analysis demonstrated significantly elevated levels of IGF-I mRNA in NT as compared to sham operated animals (312±34%, n=4, p<0.05). Northern blot analysis of tumor samples indicated no detectable expression of IGF-I mRNA (n=4). These data suggest an increased intra-hepatic role for IGF-1 in the absence of altered circulating levels of either IGF-I or GH in HCC. Furthermore the absence of IGF-I mRNA in tumorigenic tissue suggests that IGF-I is produced in response to tumor burden by non-tumorigenic liver in a paracrine/autocrine manner and may play an integral role in the maintenance of organ function and adaptation during HCC development.

Original languageEnglish
JournalFASEB Journal
Volume11
Issue number3
StatePublished - 1997
Externally publishedYes

Fingerprint

IGF Type 1 Receptor
hepatoma
insulin-like growth factor I
Insulin-Like Growth Factor I
Hepatocellular Carcinoma
Messenger RNA
liver
Liver
Tumors
neoplasms
Bearings (structural)
Protein Subunits
Northern blotting
Neoplasms
Tissue
Northern Blotting
Animals
Inbred ACI Rats
insulin-like growth factor I receptor
receptors

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

Hepatic insulin-like growth factor-I (IGF-I) receptor and mRNA expression in experimental hepatocellular carcinoma (HCC). / Mckillop, I. H.; Johnson, T.; Sabharwal, P.; Schmidt, C.; Cahill, P. A.; Sitzmann, J. V.

In: FASEB Journal, Vol. 11, No. 3, 1997.

Research output: Contribution to journalArticle

Mckillop, I. H. ; Johnson, T. ; Sabharwal, P. ; Schmidt, C. ; Cahill, P. A. ; Sitzmann, J. V. / Hepatic insulin-like growth factor-I (IGF-I) receptor and mRNA expression in experimental hepatocellular carcinoma (HCC). In: FASEB Journal. 1997 ; Vol. 11, No. 3.
@article{8c5e400dcc684b5d80683052bc53f47f,
title = "Hepatic insulin-like growth factor-I (IGF-I) receptor and mRNA expression in experimental hepatocellular carcinoma (HCC)",
abstract = "Insulin-like growth factor-I (IGF-I) is a single-polypeptide chain cytokine involved in tissue growth and differentiation. We hypothesized that altered IGF-I receptor expression in conjunction with changes in IGF-I production may be a key factor in the development and/or progression of experimental HCC. Tumorigenic H4IIE hepatoma cells were inoculated into the right hepatic lobe of ACI rats resulting in reproducible parenchymal tumor growths 14 days post-inoculation. Circulating levels of GH and IGF-I were determined in serum at 2 day intervals post-inoculation (day 2 to day 14) using RIA's. These data demonstrated no significant changes in circulating GH or IGF-I levels throughout the duration of HCC development (n=5). Cell fractions were prepared from right and left hepatic lobes of both tumor bearing and sham operated (saline vehicle only) animals 14 days post-inoculation. Western blot analysis was then performed using a polyclonal antibody raised against the IGF-I receptor that detects both a 130kDa protein (receptor α-subunit), and a second 180kDa protein (receptor pro-α-subunit). Both the α-subunit and the pro-α-subunit protein were significantly elevated in non-tumor bearing lobes (NT) as compared to tumor (T) and sham operated (Sh) membranes (246±24{\%} and 141±14{\%} respectively, n=5, p<0.05). No significant differences were observed between sham operated and tumor tissue. Northern blot analysis demonstrated significantly elevated levels of IGF-I mRNA in NT as compared to sham operated animals (312±34{\%}, n=4, p<0.05). Northern blot analysis of tumor samples indicated no detectable expression of IGF-I mRNA (n=4). These data suggest an increased intra-hepatic role for IGF-1 in the absence of altered circulating levels of either IGF-I or GH in HCC. Furthermore the absence of IGF-I mRNA in tumorigenic tissue suggests that IGF-I is produced in response to tumor burden by non-tumorigenic liver in a paracrine/autocrine manner and may play an integral role in the maintenance of organ function and adaptation during HCC development.",
author = "Mckillop, {I. H.} and T. Johnson and P. Sabharwal and C. Schmidt and Cahill, {P. A.} and Sitzmann, {J. V.}",
year = "1997",
language = "English",
volume = "11",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "3",

}

TY - JOUR

T1 - Hepatic insulin-like growth factor-I (IGF-I) receptor and mRNA expression in experimental hepatocellular carcinoma (HCC)

AU - Mckillop, I. H.

AU - Johnson, T.

AU - Sabharwal, P.

AU - Schmidt, C.

AU - Cahill, P. A.

AU - Sitzmann, J. V.

PY - 1997

Y1 - 1997

N2 - Insulin-like growth factor-I (IGF-I) is a single-polypeptide chain cytokine involved in tissue growth and differentiation. We hypothesized that altered IGF-I receptor expression in conjunction with changes in IGF-I production may be a key factor in the development and/or progression of experimental HCC. Tumorigenic H4IIE hepatoma cells were inoculated into the right hepatic lobe of ACI rats resulting in reproducible parenchymal tumor growths 14 days post-inoculation. Circulating levels of GH and IGF-I were determined in serum at 2 day intervals post-inoculation (day 2 to day 14) using RIA's. These data demonstrated no significant changes in circulating GH or IGF-I levels throughout the duration of HCC development (n=5). Cell fractions were prepared from right and left hepatic lobes of both tumor bearing and sham operated (saline vehicle only) animals 14 days post-inoculation. Western blot analysis was then performed using a polyclonal antibody raised against the IGF-I receptor that detects both a 130kDa protein (receptor α-subunit), and a second 180kDa protein (receptor pro-α-subunit). Both the α-subunit and the pro-α-subunit protein were significantly elevated in non-tumor bearing lobes (NT) as compared to tumor (T) and sham operated (Sh) membranes (246±24% and 141±14% respectively, n=5, p<0.05). No significant differences were observed between sham operated and tumor tissue. Northern blot analysis demonstrated significantly elevated levels of IGF-I mRNA in NT as compared to sham operated animals (312±34%, n=4, p<0.05). Northern blot analysis of tumor samples indicated no detectable expression of IGF-I mRNA (n=4). These data suggest an increased intra-hepatic role for IGF-1 in the absence of altered circulating levels of either IGF-I or GH in HCC. Furthermore the absence of IGF-I mRNA in tumorigenic tissue suggests that IGF-I is produced in response to tumor burden by non-tumorigenic liver in a paracrine/autocrine manner and may play an integral role in the maintenance of organ function and adaptation during HCC development.

AB - Insulin-like growth factor-I (IGF-I) is a single-polypeptide chain cytokine involved in tissue growth and differentiation. We hypothesized that altered IGF-I receptor expression in conjunction with changes in IGF-I production may be a key factor in the development and/or progression of experimental HCC. Tumorigenic H4IIE hepatoma cells were inoculated into the right hepatic lobe of ACI rats resulting in reproducible parenchymal tumor growths 14 days post-inoculation. Circulating levels of GH and IGF-I were determined in serum at 2 day intervals post-inoculation (day 2 to day 14) using RIA's. These data demonstrated no significant changes in circulating GH or IGF-I levels throughout the duration of HCC development (n=5). Cell fractions were prepared from right and left hepatic lobes of both tumor bearing and sham operated (saline vehicle only) animals 14 days post-inoculation. Western blot analysis was then performed using a polyclonal antibody raised against the IGF-I receptor that detects both a 130kDa protein (receptor α-subunit), and a second 180kDa protein (receptor pro-α-subunit). Both the α-subunit and the pro-α-subunit protein were significantly elevated in non-tumor bearing lobes (NT) as compared to tumor (T) and sham operated (Sh) membranes (246±24% and 141±14% respectively, n=5, p<0.05). No significant differences were observed between sham operated and tumor tissue. Northern blot analysis demonstrated significantly elevated levels of IGF-I mRNA in NT as compared to sham operated animals (312±34%, n=4, p<0.05). Northern blot analysis of tumor samples indicated no detectable expression of IGF-I mRNA (n=4). These data suggest an increased intra-hepatic role for IGF-1 in the absence of altered circulating levels of either IGF-I or GH in HCC. Furthermore the absence of IGF-I mRNA in tumorigenic tissue suggests that IGF-I is produced in response to tumor burden by non-tumorigenic liver in a paracrine/autocrine manner and may play an integral role in the maintenance of organ function and adaptation during HCC development.

UR - http://www.scopus.com/inward/record.url?scp=33750234967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750234967&partnerID=8YFLogxK

M3 - Article

VL - 11

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 3

ER -